Assetmark Inc. Has $1.83 Million Stake in Ascendis Pharma A/S $ASND

Assetmark Inc. raised its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 48.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,579 shares of the biotechnology company’s stock after purchasing an additional 2,787 shares during the quarter. Assetmark Inc.’s holdings in Ascendis Pharma A/S were worth $1,829,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Perceptive Advisors LLC bought a new position in Ascendis Pharma A/S in the 2nd quarter valued at $166,367,000. Wellington Management Group LLP raised its position in shares of Ascendis Pharma A/S by 95.9% during the third quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock worth $357,645,000 after acquiring an additional 880,836 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of Ascendis Pharma A/S by 2,722.9% during the third quarter. Principal Financial Group Inc. now owns 793,677 shares of the biotechnology company’s stock valued at $157,791,000 after acquiring an additional 765,561 shares during the period. Vestal Point Capital LP boosted its holdings in Ascendis Pharma A/S by 200.0% in the third quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company’s stock valued at $119,286,000 after acquiring an additional 400,000 shares during the last quarter. Finally, Spyglass Capital Management LLC bought a new position in Ascendis Pharma A/S in the third quarter valued at about $77,267,000.

Ascendis Pharma A/S Trading Up 0.4%

Shares of ASND opened at $245.38 on Tuesday. The stock has a market capitalization of $15.31 billion, a price-to-earnings ratio of -55.77 and a beta of 0.49. Ascendis Pharma A/S has a 12 month low of $150.89 and a 12 month high of $250.74. The firm has a fifty day simple moving average of $230.36 and a 200 day simple moving average of $217.37.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Thursday, February 12th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.58). The business had revenue of $290.38 million during the quarter, compared to analysts’ expectations of $285.35 million. As a group, research analysts predict that Ascendis Pharma A/S will post 4.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ASND has been the topic of several analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $300.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Wolfe Research reiterated an “outperform” rating and set a $260.00 target price on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Stifel Nicolaus set a $332.00 price target on Ascendis Pharma A/S in a research note on Wednesday, March 4th. Wells Fargo & Company raised their price target on Ascendis Pharma A/S from $322.00 to $330.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $255.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Ascendis Pharma A/S has an average rating of “Moderate Buy” and an average price target of $291.56.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.